Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination

NCT07294950 · Recruiting

Last updated 2026-05-28

This clinical trial tests how stopping the medication semaglutide affects weight, blood pressure, and appetite in adults with obesity.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 98 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2026-02 · est. completion 2029-05

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT07294950 ↗

Description as written by the study sponsor.

Semaglutide is a medication from the class of drugs called glucagon-like peptide-1 agonists that promote weight loss. There is little clinical data on the best strategy to achieve weight maintenance following weight reduction induced by semaglutide. For people who need to discontinue treatment, it is unknown whether the weight regain, its accompanied health benefits could be ameliorated with a gradual reduction in semaglutide. The investigators will study if a gradual reduction of semaglutide is associated with different heart risk profile and hormones involved in energy regulation as compared to immediate treatment cessation.

Treatments tested

Gradual dose reduction of semaglutide Drug

Pparticipants will reduce semaglutide dosage by 25% every 4-weeks until complete treatment cessation at week 16
Abrupt cessation of semaglutide Drug

Cessation of semaglutide at 16-weeks

Main thing measured	Differences in changes in body weight between each study group
Sponsor	Mount Sinai Hospital, Canada
Conditions studied	Obesity (Disorder), Weight Change, Blood Pressure Monitoring, Appetite Regulation
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07294950 ↗